Narcolepsy secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) Created page with "__NOTOC__ {{Narcolepsy}} {{CMG}}; {{AE}} ==Overview== There are no established measures for the secondary prevention of [disease name]. OR Effective measures for the secon..." |
Homa Najafi (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Narcolepsy}} | {{Narcolepsy}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{MWH}} | ||
==Overview== | ==Overview== | ||
Line 25: | Line 25: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Medicine]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Neurology]] |
Latest revision as of 14:42, 31 July 2020
Narcolepsy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Narcolepsy secondary prevention On the Web |
American Roentgen Ray Society Images of Narcolepsy secondary prevention |
Risk calculators and risk factors for Narcolepsy secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Muhammad Waleed Haider, M.D.[2]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]